WO2003013499A2 - Drugs for vasculopaties - Google Patents

Drugs for vasculopaties Download PDF

Info

Publication number
WO2003013499A2
WO2003013499A2 PCT/EP2002/008374 EP0208374W WO03013499A2 WO 2003013499 A2 WO2003013499 A2 WO 2003013499A2 EP 0208374 W EP0208374 W EP 0208374W WO 03013499 A2 WO03013499 A2 WO 03013499A2
Authority
WO
WIPO (PCT)
Prior art keywords
acid
methyl
nitrooxy
alpha
formula
Prior art date
Application number
PCT/EP2002/008374
Other languages
French (fr)
Other versions
WO2003013499A3 (en
Inventor
Piero Del Soldato
Original Assignee
Nicox S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicox S.A. filed Critical Nicox S.A.
Priority to AU2002333276A priority Critical patent/AU2002333276A1/en
Publication of WO2003013499A2 publication Critical patent/WO2003013499A2/en
Publication of WO2003013499A3 publication Critical patent/WO2003013499A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • the present invention relates to the use of drugs in the prevention and/or treatment of vasculopathies .
  • vascular cells cells of the vasal smooth musculature ceils, endothelial cells
  • haematic cells platelets, leucocytes, monocytes/macrophages, etc.
  • Vasculopathies and diseases related thereto are pathological conditions associated to an altered haematochemical and clinical picture, which shows itself with hyperglycemia and/or hyperinsulinemia, hyperlipide ia and/or hydric-saline retention and/or hyperproliferation of vasal and/or tu oral cells, and/or prothrombotic and procoagulant activity, etc.
  • Vasculopathies can facilitate the growth of other pathologies such obesity, diabetes and cardiovascular diseases such for example myocardial, cerebral and/or peripheral ischaemias, retinopathies, polyneuropathies, gastroenteropathies, ne- phropa-thies, etc., hypertension (general and local at pulmonary, coronary, portal, renal level, etc.) atherosclerosis, Alzheimer disease, cancer.
  • cardiovascular diseases such for example myocardial, cerebral and/or peripheral ischaemias, retinopathies, polyneuropathies, gastroenteropathies, ne- phropa-thies, etc.
  • hypertension generally and local at pulmonary, coronary, portal, renal level, etc.
  • Alzheimer disease cancer.
  • vasculopathies Also particular pathologies such as the X syndrome (or insulin resistance) and the vasculopathy from drugs are comprised in vasculopathies.
  • the ideal approach is to operate on the various cell processes, i.e. to prevent the pathological activation of the aforesaid cells, which causes the growth and the progress of the pathological process affecting the cardiovascular system.
  • Statines, rapamycin and the radiotherapeutic treatment are active only on the smooth musculature but not on the other cell populations.
  • the results obtained with said pharmacological treatments and with the radiotherapy are only partially satisfactory and therefore it is necessary to increase dosages with consequent even serious side effects.
  • An object of the present invention is therefore the use in vasculopathies of drugs, or salts thereof, having the following general formula (I) :
  • R is the radical of formula (All)
  • Ri is phenyl, or a 2, 6-dichlorophenylamino- group; R 6 is hydrogen or one halogen atom, preferably fluorine; or Ri and R 6 form together the radical of formula (Ala);
  • the precursor compound of B being selected from the following: aminoacids, selected from the following: L- carnosirie, anserine, selenocysteine, selenome- thionine, penicillamine, N-acetylpenicillamine, cysteine, N-acetylcysteine, glutathione or its esters, preferably ethyl or isopropyl ester; hydroxyacids, selected from the following: gallic acid, ferulic acaid, gentisic acid, citric acid, caffeic, dihydrocaffeic acid, p-cumaric acid, vanillic acid; aromatic and hetrocyclic polyalcohols, selected from the following: nordihydroguai
  • Y is :
  • nIX is an integer comprised between 0 and 3, preferably 1
  • nllX is an integer comprised between 1 and 3, preferably 1;
  • R TIX , RTIX', T I IX ⁇ R II '/ equal to or different from each other are H or linear or branched C ⁇ -C 4 alkyl; preferably R TIX , R T ⁇ x ' , R T nx, RTIIX' are H.
  • Y 3 is a saturated, unsaturated or aromatic heterocy-rod ring containing one or two nitrogen atoms, having 5 or 6 atoms, or Y can be: Yo, selected from the following: an alkylenoxy group R'O wherein R' is a linear or branched when possible C ⁇ -C 20 , preferably having from 2 to 6 carbon atoms, or a cycloal- kylene having from 5 to 7 carbon atoms, in the cycloalkylene ring one or more carbon atoms can be substituted by heteroatoms, the ring can have side chains of R' type, R' being as above; or one of the following groups: -(CH 2 - CH 2 O)'nf
  • nf ' is an integer from 1 to 6 preferably from 1 to 4 ;
  • R if H, CH 3 and nf is an integer from 1 to
  • Y is Y AR and is selected from the following:
  • n3 is an integer from 0 to 3 and n3 ' is an integer from 1 to 3;
  • YAR2 is an integer from 0 to 3 and n3 ' is an integer from 1 to 3;
  • n3 and n3 ' have the above meaning.
  • R AI is CH 3
  • Ri is the phenyl group in position 4 of the ring
  • R 6 F in position 3
  • the so defined radical is that of the precursor drug Flurbiprofen
  • R A ⁇ is CH 3
  • Ri and R 6 are in position 4 and 5 of the ring and form together the radical of formula (Ala)
  • the so defined radical is that of the precursor drug Naproxen
  • R A ⁇ is H
  • Ri is the 2,6- dichlorophenylamino group and is in position 2 of the ring
  • R 6 H
  • the so defined radical is that of the precursor drug Diclofenac.
  • Y 3 is selected from the following:
  • Y 3 is an aromatic ring having 6 atoms, containing one nitrogen atom, said aromatic ring having the two free valences in position 2 and 6.
  • Y 3 is Y12 (pyridyl) substituted in position 2 and 6.
  • the bonds can also be in an asymmetric position, for example Y12 (pyridyl) can be substituted also in position 2 and 3; Yl (pyrazol) can be 3, 5-disubstituted.
  • the precursors of Y p wherein the oxygen free valence is saturated with H and the free valence of the end carbon is saturated either with a carboxylic or an hydroxyl group, are compounds available on the market or can be obtained by meth ⁇ ods known in the prior art .
  • the functional linking groups between, respectively, R and X 2 , between X 2 and Y, or between R and Y, can be ester, am- ideor thioester.
  • the precursor compounds of B of the above groups are pre- pard according to the methods known in the prior art and described for example in "The Merck Index", 12th Ed. (1996), herein incorporated by reference.
  • the preferred compounds of formula (I) are the following: 2-Fluoro- ⁇ -methyl [1, 1' -biphenyl] -4-acetic acid 4- (nitrooxy) butyl ester (V)
  • the compounds of formula (I) are generally obtained by methods known in the prior art, see for example patent applications WO 00/61537, WO 00/51988, WO 95/30641, in the name of the Applicant .
  • the compounds of formula (I) usable in the present invention have one or more chiral centres, they can be in a race ic form or as mixtures of diastereoisomers, as single en- antiomers or single diastereoisomers; when they show a geometric asymmetry, the compounds in the cis or trans form can be used.
  • a salifiable functional group for example an aminic or heterocyclic nitrogen
  • organic solvent such as for example acetonitrile, tetrahy- drofuran, with an equimolar amount of the corresponding organic or inorganic acid.
  • usable organic acids are the following: ox ⁇ alic, tartaric, maleic, succinic, citric acids.
  • Examples of usable inorganic acids are the following: nitric, hydrochloric, sulphuric, phosphoric acids. Nitric and hydrochloric acids are preferred.
  • the vasculopathy is significantly reduced and in particular the restenosis process which can grow in people subjected to angioplasty and in particular , in those more at risk such as old people, diabetic, hyperlipidemic people.
  • the amount on a molar basis of the active principle in said formulations is equal to or lower than the maximum posol- ogy indicated for the precursor drugs. Also higher doses can be used considering their very good tolerability.
  • the daily doses of the precursor drugs can be found in the publications of the prior art, such as for example in "Physician's Desk reference".
  • Wistar male rats of 300-350 g weight were anaesthetized by intraperitoneal injection of ketamine (100 g/kg) and xylazine (5 mg/kg) and subjected to angioplasty according to the procedure described by Indolfi et Al . , Circulation 1995 92 1230-1235, by using a little balloon catheter.
  • the balloon was first introduced in the aortic arch through the right carotid, then swollen and passed three times forth and back in the duct lumen.
  • the animals were divided in the two groups indicated below and subjected for 14 days to the pharmacological treatment as described ereunder: one group was treated by os by means of a gastric cannula with NO-Flurbiprofen at the dose of 10 mg/kg dissolved in polyethylene glycol (PEG 400), and the other group (control) received only the carrier (PEG 400, 0.2 ml/rat).
  • one group was treated by os by means of a gastric cannula with NO-Flurbiprofen at the dose of 10 mg/kg dissolved in polyethylene glycol (PEG 400), and the other group (control) received only the carrier (PEG 400, 0.2 ml/rat).
  • the animals were sacrificed and the carotids removed. For each artery no. 6 sections having a thickness of 6 ⁇ m were obtained. Stomachs were also removed and inspected to evaluate damages to the gastric mucosa. Areas of both bleeding lesions and non bleeding lesions were determined.
  • the thicknesses, respectively, of the middle and neoin- tima tunica, and of the duct wall were measured.
  • the results reported in Table 1 are expressed as percentage of restenosis and have been calculated as a ratio between the thickness of the neointima tunica to that of the middle tunica (M/N) measured in the sections of the various groups, assuming equal to 100 the N/M ratio of the control group.
  • Example FI is repeated but using NO-Flurbiprofen at the dose of 30 mg/Kg. The results are reported in Table 1.
  • Example FI is repeated but using Flurbiprofen at the dose of 7 mg/Kg. The results are reported in Table 1.
  • Example FI is repeated but using Flurbiprofen at the dose of 21 mg/Kg. The results are reported in Table 1.
  • Example FI is repeated but using NO-Ketorolac at the dose of 10 mg/Kg. Comments on Table 1
  • NO-Ketorolac appears not very effective with respect to NO-Flurbiprofen and at effective doses it produces gastric lesions .

Abstract

Use for the vasculopathy treatment of compounds or salts thereof, having the following general formula (I): wherein R is the radical of formula (AII), the radicals RAI, R1, and R6 of formula (AII), and the bivalent linking groups B and C of the general (I) being as defined in the invention.

Description

DRUGS FOR VASCULOPATHIES
- -λ- -k ■*• "k
The present invention relates to the use of drugs in the prevention and/or treatment of vasculopathies .
The most serious cardiovascular pathologies (among which restenosis, atherosclerosis, miocardium infarct, peripheral and central vascular diseases etc.) are characterized by a pathological activation of vascular cells (cells of the vasal smooth musculature ceils, endothelial cells) and haematic cells (platelets, leucocytes, monocytes/macrophages, etc.).
Vasculopathies and diseases related thereto are pathological conditions associated to an altered haematochemical and clinical picture, which shows itself with hyperglycemia and/or hyperinsulinemia, hyperlipide ia and/or hydric-saline retention and/or hyperproliferation of vasal and/or tu oral cells, and/or prothrombotic and procoagulant activity, etc. Vasculopathies can facilitate the growth of other pathologies such obesity, diabetes and cardiovascular diseases such for example myocardial, cerebral and/or peripheral ischaemias, retinopathies, polyneuropathies, gastroenteropathies, ne- phropa-thies, etc., hypertension (general and local at pulmonary, coronary, portal, renal level, etc.) atherosclerosis, Alzheimer disease, cancer.
Also particular pathologies such as the X syndrome (or insulin resistance) and the vasculopathy from drugs are comprised in vasculopathies.
An unitary therapeutic approach able to prevent and/or reduce vasculopathies does not exist.
The ideal approach is to operate on the various cell processes, i.e. to prevent the pathological activation of the aforesaid cells, which causes the growth and the progress of the pathological process affecting the cardiovascular system.
At present the drugs used for vasculopathies and the used therapeutic approaches inhibit only one cell population, therefore they act only on one phase of the process, with only partially satisfactory results.
Statines, rapamycin and the radiotherapeutic treatment are active only on the smooth musculature but not on the other cell populations. The results obtained with said pharmacological treatments and with the radiotherapy are only partially satisfactory and therefore it is necessary to increase dosages with consequent even serious side effects.
The need was felt to have available drugs allowing to carry out an effective therapeutic treatment of vasculopathies, overcoming the drawbacks associated to the therapeutic and surgical treatments at present used, and being effective in inhibiting the pathological activation of various cell populations of the cardiovascular system and besides not resulting toxic, in particular at gastric level, and furthermore being usable for prolonged treatments without side effects.
This technical problem has been solved by the Applicant using a specific class of drugs. Surprisingly and unexpectedly the Applicant has found that specific nitrooxyderivatives of defined compounds, e.g. flurbiprofen, naproxen and diclofenac are active in the vasculopathy treatment, acting on the involved cell processes. Said result is surprising since other nitrooxyderivatives, such as for example the piroxicam and ke- torolac derivatives, have not proved to be active at non toxic doses .
An object of the present invention is therefore the use in vasculopathies of drugs, or salts thereof, having the following general formula (I) :
0
R-C-(B)b-(C)^N02
(I) wherein: cO is an integer and is 0 or 1; bO is an integer and is 0 or 1, with the proviso that cO and bO cannot be contemporaneously equal to zero.
R is the radical of formula (All)
E CCHH3—
Figure imgf000004_0001
(All) wherein:
Figure imgf000004_0002
Ri is phenyl, or a 2, 6-dichlorophenylamino- group; R6 is hydrogen or one halogen atom, preferably fluorine; or Ri and R6 form together the radical of formula (Ala);
Figure imgf000004_0003
(Ala) -TB-X2-TBι- wherein TB and TBi are equal or different;
TB = X, wherein X = 0, S, NRιC, Ric is H or a linear or branched alkyl having from 1 to 5 carbon atoms ; TBI = (CO)tx or (X)txχr wherein tx and txx have the value of 0 or 1; with the proviso that tx = 1 when txx = 0, tx = 0 when txx = 1; X is as above; X2, bivalent radical, is such that the corresponding precursor of B, -TB-X≥-TBI- wherein the free valence of TB is saturated with Z, and that of TBι with OZ, Z or with -N(ZI) (Z11), wherein Z = H, C1-C10, preferably C3.-C5 alkyl linear or branched when possible, Z1, Z11 equal or different have the values of Z as above, depending on that TB and/or TBI = CO or X, in function of the values of tx and txx; the precursor compound of B being selected from the following: aminoacids, selected from the following: L- carnosirie, anserine, selenocysteine, selenome- thionine, penicillamine, N-acetylpenicillamine, cysteine, N-acetylcysteine, glutathione or its esters, preferably ethyl or isopropyl ester; hydroxyacids, selected from the following: gallic acid, ferulic acaid, gentisic acid, citric acid, caffeic, dihydrocaffeic acid, p-cumaric acid, vanillic acid; aromatic and hetrocyclic polyalcohols, selected from the following: nordihydroguaiaretic acid, quercetin, catechin, kaempferol, sulphurethyne, ascorbic acid, isoascorbic acid, hydroquinone, gossypol, reductic acid, methoxyhydroquinone, hydroxyhydroquinone, propyl gallate, saccharose, 3, 5-di-tertbutyl-4-hydroxybenzyl-thio glycolate, p-cumaric alcohol, 4-hydroxy- phenylethylalcohol, coniferyl alcohol, allopu- rinol; compounds containing at least one free acid function, selected from the following: 3,3'- thiodipropionic acid, fumaric acid, dihydroxy- maleic acid, edetic acid; C is the bivalent radical -Tc-Y- wherein when bO = cO = 1: Tc = (CO) when tx = 0, Tc = X when txx = 0, X being as above defined, when bO = 0 : Tc = X, X being as above defi- ned, when cO = 0 tx = 0 , TBI = X = -0-;
Y is :
Figure imgf000006_0001
( III ) wherein : nIX is an integer comprised between 0 and 3, preferably 1; nllX is an integer comprised between 1 and 3, preferably 1;
RTIX, RTIX', TIIXΛ R II '/ equal to or different from each other are H or linear or branched Cι-C4 alkyl; preferably RTIX, RTιx', RTnx, RTIIX' are H. Y3 is a saturated, unsaturated or aromatic heterocy- clic ring containing one or two nitrogen atoms, having 5 or 6 atoms, or Y can be: Yo, selected from the following: an alkylenoxy group R'O wherein R' is a linear or branched when possible Cι-C20, preferably having from 2 to 6 carbon atoms, or a cycloal- kylene having from 5 to 7 carbon atoms, in the cycloalkylene ring one or more carbon atoms can be substituted by heteroatoms, the ring can have side chains of R' type, R' being as above; or one of the following groups: -(CH2- CH2 O)'nf
Figure imgf000007_0001
wherein nf ' is an integer from 1 to 6 preferably from 1 to 4 ;
( O)nf-
Figure imgf000007_0002
wherein Rif = H, CH3 and nf is an integer from 1 to
6; preferably from 1 to 4; or Y is YAR and is selected from the following:
YftRi :
-
Figure imgf000007_0003
wherein n3 is an integer from 0 to 3 and n3 ' is an integer from 1 to 3; YAR2 :
Figure imgf000007_0004
wherein n3 and n3 ' have the above meaning.
When in formula (All) RAI is CH3, Ri is the phenyl group in position 4 of the ring, R6 = F in position 3, the so defined radical is that of the precursor drug Flurbiprofen; when in formula (All) RAι is CH3, Ri and R6 are in position 4 and 5 of the ring and form together the radical of formula (Ala) , the so defined radical is that of the precursor drug Naproxen; when in formula (All) RAι is H, Ri is the 2,6- dichlorophenylamino group and is in position 2 of the ring, R6 = H, the so defined radical is that of the precursor drug Diclofenac.
Preferably Y3 is selected from the following:
(YD (Y2; (Y3! ( Y4 ) ( Y5 ) ( Y6 )
Figure imgf000008_0002
(Y7) IY8 ( Y9 ) ( Y10 ) ( Yl l )
Figure imgf000008_0003
(Y12) (Y13) (Y14) (Y15)
Preferably Y3 is an aromatic ring having 6 atoms, containing one nitrogen atom, said aromatic ring having the two free valences in position 2 and 6.
The preferred of Y3 is Y12 (pyridyl) substituted in position 2 and 6. The bonds can also be in an asymmetric position, for example Y12 (pyridyl) can be substituted also in position 2 and 3; Yl (pyrazol) can be 3, 5-disubstituted.
The precursors of Yp, wherein the oxygen free valence is saturated with H and the free valence of the end carbon is saturated either with a carboxylic or an hydroxyl group, are compounds available on the market or can be obtained by meth¬ ods known in the prior art .
The functional linking groups between, respectively, R and X2, between X2 and Y, or between R and Y, can be ester, am- ideor thioester. The precursor compounds of B of the above groups are pre- pard according to the methods known in the prior art and described for example in "The Merck Index", 12th Ed. (1996), herein incorporated by reference.
The preferred compounds of formula (I) are the following: 2-Fluoro-α-methyl [1, 1' -biphenyl] -4-acetic acid 4- (nitrooxy) butyl ester (V)
Figure imgf000009_0001
(V) Trans-3- [ 4- [2-f luoro-alpha-methyl ( 1 , 1 ' -biphenyl ) -4-acetyl oxy] -3-methoxyphenyl] -2-propenoic acid 4- (nitrooxy) butyl ester (VI )
Figure imgf000009_0002
(VI ) 2-f luoro-alpha-methyl [1 , 1' -biphenyl] -4-acetic acid 3- (nitrooxy methyl ) phenyl ester (VII )
Figure imgf000009_0003
(VII) (S) -N-acetyl-S- [2-fluoro-alpha-methyl (1, 1' -biphenyl) -4- acetyl] cysteine 4- (nitrooxy) butyl ester (VIII)
Figure imgf000010_0001
(VIII) 2-fluoro-alpha-methyl [1, 1' -biphenyl] -4-acetic acid 6- (nitrooxy methyl) -2-methylpyridinyl ester (IX)
Figure imgf000010_0002
(IX) (S) -6-methoxy-alpha-methyl-2-naphthalenacetic acid nitrooxy) butyl ester (X)
Figure imgf000010_0003
(X)
(S) -6-methoxy-alpha-methyl-2-naphthalenacetic acid (nitrooxy methyl) phenyl ester (XI)
Figure imgf000010_0004
(XI) (S) -6-methoxy-alpha-methyl-2-naphthalenacetic acid (nitrooxy ethyl) -2-methylpyridinyl ester (XII)
Figure imgf000011_0001
rieo
(XID Trans-3- [4- [6-methoxy-alpha-methyl-2-naphthalenacetyl oxy] -3-methoxyphenyl] -2-propenoic acid 4- (nitrooxy) butyl ester (XIII)
Figure imgf000011_0002
(XIII) (S, S) -N-acetyl-S- ( 6-methoxy-alpha-methyl-2-naphthalena- cetyl) cysteine 4- (nitrooxy) butyl ester (XIV)
Figure imgf000011_0003
ileO
(XIV)
2- [ (2, 6-dichlorophenyl) aminojbenzenacetic acid [nitrooxy) butyl ester (XV)
Figure imgf000011_0004
(XV) 2- [ (2, 6-dichlorophenyl) aminojbenzenacetic acid 4- (nitro oxymethyl) phenyl ester (XVI)
Figure imgf000012_0001
2- [ ( 2 , 6-dichlorophenyl ) a ino] benzenacetic acid 6- (nitro oxymethyl ) -2-methylpyridinyl hydrochloride ester (XVII )
Figure imgf000012_0002
(XVII)
The compounds of formula (I) are generally obtained by methods known in the prior art, see for example patent applications WO 00/61537, WO 00/51988, WO 95/30641, in the name of the Applicant .
When the compounds of formula (I) usable in the present invention have one or more chiral centres, they can be in a race ic form or as mixtures of diastereoisomers, as single en- antiomers or single diastereoisomers; when they show a geometric asymmetry, the compounds in the cis or trans form can be used.
When in the molecule of the compounds of formula (I) a salifiable functional group is present, for example an aminic or heterocyclic nitrogen, it is possible to use the corresponding salts of the above compounds, obtainable by reaction in organic solvent such as for example acetonitrile, tetrahy- drofuran, with an equimolar amount of the corresponding organic or inorganic acid. Examples of usable organic acids are the following: ox¬ alic, tartaric, maleic, succinic, citric acids.
Examples of usable inorganic acids are the following: nitric, hydrochloric, sulphuric, phosphoric acids. Nitric and hydrochloric acids are preferred.
By using the products of the invention the vasculopathy is significantly reduced and in particular the restenosis process which can grow in people subjected to angioplasty and in particular, in those more at risk such as old people, diabetic, hyperlipidemic people.
The therapeutic use of the products described in the present invention results advantageous, as said, since these compounds are able to act both on the duct (endothelial and vasal smooth musculature cells) and on haematic cells (platelets, leucocytes) and ha-ematic factors.
The compounds of formula (I) or the corresponding salts are formulated in the corresponding pharmaceutical compositions for parenteral, oral use according to the techniques well known in the prior art, together with the usual excipi- ents; see for example the volume "Remington's Pharmaceutical Sciences 15th Ed.".
The amount on a molar basis of the active principle in said formulations is equal to or lower than the maximum posol- ogy indicated for the precursor drugs. Also higher doses can be used considering their very good tolerability. The daily doses of the precursor drugs can be found in the publications of the prior art, such as for example in "Physician's Desk reference".
The following Examples illustrate the invention but are not limitative of the scope of the same. EXAMPLE FI
Efficacy of Flurbiprofen and of 2-fluoro-alpha-methyl-4- diphenylacetic acid (4-nitrooxy) butyl ester in an experimental model of restenosis induced in rats
2-fluoro-alpha-methyl-4-diphenylacetic acid (4- nitrooxy) butyl ester (NO-Flurbiprofen) was synthesized as described in Example 1 of patent application WO 95/30641.
Wistar male rats of 300-350 g weight were anaesthetized by intraperitoneal injection of ketamine (100 g/kg) and xylazine (5 mg/kg) and subjected to angioplasty according to the procedure described by Indolfi et Al . , Circulation 1995 92 1230-1235, by using a little balloon catheter. The balloon was first introduced in the aortic arch through the right carotid, then swollen and passed three times forth and back in the duct lumen.
After the vascular damage the animals were divided in the two groups indicated below and subjected for 14 days to the pharmacological treatment as described ereunder: one group was treated by os by means of a gastric cannula with NO-Flurbiprofen at the dose of 10 mg/kg dissolved in polyethylene glycol (PEG 400), and the other group (control) received only the carrier (PEG 400, 0.2 ml/rat).
The animals were sacrificed and the carotids removed. For each artery no. 6 sections having a thickness of 6 μm were obtained. Stomachs were also removed and inspected to evaluate damages to the gastric mucosa. Areas of both bleeding lesions and non bleeding lesions were determined.
3 out of the 6 sections of each artery were stained with hematoxylin and eosin to evidence the different types of cells, the remaining 3 sections were stained first with aldehyde fuchsin and then with the Gieson solution to evidence the internal elastic lamina. The sections were photographed and the imagines were analyzed by an image analysis system (Qwin Lite, Leica, Milan) .
The thicknesses, respectively, of the middle and neoin- tima tunica, and of the duct wall were measured. The results reported in Table 1 are expressed as percentage of restenosis and have been calculated as a ratio between the thickness of the neointima tunica to that of the middle tunica (M/N) measured in the sections of the various groups, assuming equal to 100 the N/M ratio of the control group.
The results are reported in Table 1. EXAMPLE F2
Example FI is repeated but using NO-Flurbiprofen at the dose of 30 mg/Kg. The results are reported in Table 1. EXAMPLE F3 Comparative
Example FI is repeated but using Flurbiprofen at the dose of 7 mg/Kg. The results are reported in Table 1. EXAMPLE F4 Comparative
Example FI is repeated but using Flurbiprofen at the dose of 21 mg/Kg. The results are reported in Table 1. EXAMPLE F5 Comparative
In this Example the 5-benzoyl-2, 3-dihydro-lH-pyrrolidin- 1-carboxylic acid (4-nitrooxy) butyl ester (NO-ketorolac) is used, sinthesized as described in Example IF of patent application WO 95/30641.
Example FI is repeated but using NO-Ketorolac at the dose of 10 mg/Kg. Comments on Table 1
The results reported in Table 1 show that the restenosis induced by the lesion with the little balloon catheter is significantly reduced by administering low doses of NO- Flurbiprofen. Flurbiprofen is not very effective in reducing restenosis even at the dose of 20 mg/Kg. The number of gastric lesions following administration of Flurbiprofen is very high in the confront of NO-Flurbiprofen.
NO-Ketorolac appears not very effective with respect to NO-Flurbiprofen and at effective doses it produces gastric lesions .
Table 1
Figure imgf000017_0001

Claims

Use for the preparation of drugs for the vasculopathy treatment, of compounds, or salts thereof, having the following general formula (I) :
0 R-C-(B)So-(C)Hb- 02
(I) wherein: cO is an integer and is 0 or 1; bO is an integer and is 0 or 1, with the proviso that cO and bO cannot be contemporaneously equal to zero.
R is the radical of formula (All)
Figure imgf000018_0001
(All) wherein: RAI is CH3 or H;
Ri is phenyl, or a 2, 6-dichlorophenylamino- group; Re is hydrogen or one halogen atom, preferably fluo¬ rine; or Ri and Re form together the radical of formula (Ala) ;
Figure imgf000018_0002
(Ala)
B = -TB-X2-TBi- wherein TB and TBI are equal or different;
TB = X, wherein X = 0, S, NRχc, Ric is H or a linear or banched alkyl having from 1 to 5 carbon atoms; TBI = (CO)tx or (X) tχx, wherein tx and txx have the value of 0 or 1; with the proviso that tx = 1 when txx = 0, tx = 0 when txx = 1; X is as above; X2, bivalent radical, is such that the corresponding precursor of B, -TB-X2-TBI- wherein the free valence of TB is saturated with Z, and that of TBI with OZ, Z or with -N(ZI) (Z11) , wherein Z = H, Ci-Cio, preferably C1-C5 alkyl linear or branched when possible, Z1, Z11 equal or different have the values of Z as above, depending on that TB and/or TBι = CO or X, in function of the values of tx and txx; the precursor compound of B being selected from the following: aminoacids, selected from the following: L- carnosine, anserine, selenocysteine, selenome- thionine, penicillamine, N-acetylpenicillamine, cysteine, N-acetilcysteine, glutathione or its esters, preferably ethyl or isopropyl ester; hydroxyacids, selected from the following: gallic acid, ferulic acid, gentisic acid, citric acid, caffeic, dihydrocaffeic acid, p-cumaric acid, vanillic acid; - aromatic and heterocyclic polyalcohols, selected from the following: nordihydroguaiaretic acid, quercetin, catechin, kaempferol, sul- phurethyne, ascorbic acid, isoascorbic acid, hydroquinone, gossypol, reductic acid, methoxy- hydroquinone, hydroxyhydroquinone, propyl gal- late, saccharose, 3, 5-di-tertbutyl-4- hydroxybenzyl-thio glycolate, p-cumaric alcohol, 4-hydroxy-phenylethylalcohol, coniferyl alcohol, allopurinol; compounds containing at least one free acid function, selected from the following: 3,3'- thiodipropionic acid, fumaric acid, dihydroxy- maleic acid, edetic acid; C being the bivalent radical -Tc-Y- wherein
Tc = (CO) when tx = 0, Tc = X when txx = 0, X being as above defined;
Y is :
Yr
R -TIX R ■TIIX
■[C] nIX Y3— [Clπt x-O
R ^•TTI R i TTIIX
( I I I ) wherein : nIX is an integer comprised between 0 and 3, preferably 1; nllX is an integer comprised between 1 and 3, preferably 1;
RTx, RTIX1, RTIIXΛ RTIIX'Λ equal to or different from each other are H or linear or branched Cι~C alkyl; preferably Rιx, RTIX- , RTIIX, RTIX- are H. Y3 is a saturated, unsaturated or aromatic hetero- cyclic ring containing one or two nitrogen atoms, having 5 or 6 atoms, or Y can be: Yo, selected from the following: an alkylenoxy group R'O wherein R' is a linear or branched when possible Cι-C20, preferably having from 2 to 6 carbon atoms, or a cycloalkylene having from 5 to 7 carbon atoms, in the cycloalkylene ring one or more carbon atoms can be substituted by het- eroatoms, the ring can have side chains of R' type,
R' being as above; or one of the following groups:
(CH2- CH2-O) 'nf-
Figure imgf000021_0001
wherein nf ' is an integer from 1 to 6 preferably from 1 to 4 ;
( 0)nf
Figure imgf000021_0002
wherein Rif = H, CH3 and nf is an integer from 1 to
6 ; preferably from 1 to 4 ; or Y is YAR and is selected from the following :
Figure imgf000021_0003
wherein n3 is an integer from 0 to 3 and n3 ' is an integer from 1 to 3;
Figure imgf000021_0004
wherein n3 and n3 ' have the above meaning. 2. Use according to claim 1, wherein: when in formula (All) RAI is CH3, Rx is the phenyl group in position 4 of the ring, R5 = F in position 3, the so defined radical is that of the precursor drug Flurbiprofen; when in formula (All) RAΣ is CH3, Ri and R6 are in po¬ sition 4 and 5 of the ring and form together the radical of formula (Ala) , the so defined radical is that of the precursor drug Naproxen; when in formula (All) RAΪ is H, Ri is the 2,6- dichlorophenylamino- group and is in position 2 of the ring, R6 = H, the so defined radical is that of the precursor drug Diclof'enac.
Use according to claims 1-2, wherein Y3 is selected from the following:
Figure imgf000022_0001
[YD : Y2 ' (Y3) (Y4) (Y5) (Y6J
Figure imgf000022_0002
(Y12 ;γi3; (Y14) (Yi5;
Use according to claim 3, wherein Y3 is an aromatic ring having 6 atoms, containing one nitrogen atom, having the two free valences in position 2 and 6.
5. Use according to claims 3-4, wherein Y3 is Y12 (pyridyl) . 6. Use according to claims 1-5, wherein the preferred com¬ pounds of formula (I) are the following:
2-Fluoro-α-methyl [1, 1' -biphenyl] -4-acetic acid 4- (nitrooxy) butyl ester (V)
Figure imgf000023_0001
(V)
Trans-3- [4- [2-fluoro-alpha-methyl (1, 1' -biphenyl) -4- acetyloxy] -3-methojcyphenyl] -2-propenoic acid 4- (nitrooxy) butyl ester (VI)
Figure imgf000023_0002
(VI) 2-Fluoro-alpha-methyl [1,1' -biphenyl] -4-acetic acid 3- (nitrooxy methyl) phenyl ester (VII)
Figure imgf000023_0003
(VII) (S) -N-acetyl-S- [2-f luoro-alpha-methyl (1,1'- biphenyl) -4-acetyl] cysteine 4- (nitrooxy) butyl ester
(VIII)
Figure imgf000024_0001
(VIII) 2-Fluoro-alpha-methyl [1,1' -biphenyl] -4-acetic acid - (nitrooxy methyl) -2-methylpyridinyl ester (IX)
Figure imgf000024_0002
(IX) (S) -6-methoxy-alpha-methyl-2-naphthalenacetic acid - (nitrooxy) butyl ester (X)
Figure imgf000024_0003
(X)
(S ) -6-methoxy-alpha-methyl-2-naphthalenacetic acid - (nitrooxy methyl ) phenyl ester (XI )
Figure imgf000024_0004
(S) -6-methoxy-alpha-methyl-2-naphthalenacetic acid - (nitrooxymethyl) -2-methylpyridinyl ester (XII) H
Figure imgf000025_0001
(xii)
Trans-3-'[4- [6-methoxy-alpha-methyl-2-naphthalen ace- tyloxy] -3-methoxyphenyl] -2-propenoic acid 4- (nitrooxy) butyl ester (XIII)
Figure imgf000025_0002
(XIII) (S, S) -N-acetyl-S- ( 6-methoxy-alpha-methyl-2- naphthalene acetyl) cysteine 4- (nitrooxy) butyl ester (XIV)
Figure imgf000025_0003
(XIV) 2- [ (2, 6-dichlorophenyl) amino] benzenacetic acid [nitrooxy) butyl ester (XV)
Figure imgf000025_0004
(XV) 2- [ (2, 6-dichlorophenyl) amino] benzenacetic acid (nitrooxymethyl) phenyl ester (XVI)
Figure imgf000026_0001
2- [ (2 , 6-dichlorophenyl ) amino] benzenacetic acid 6- (nitrooxymethyl ) -2-methylpyridinyl hydrochloride ester (XVII )
Figure imgf000026_0002
(XVII) Use according to claims 1-6, wherein the compounds of formula (I) or the corresponding salts are formulated in the corresponding pharmaceutical compositions for paren- teral, oral use.
PCT/EP2002/008374 2001-08-09 2002-07-26 Drugs for vasculopaties WO2003013499A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002333276A AU2002333276A1 (en) 2001-08-09 2002-07-26 Drugs for vasculopaties

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001MI001744A ITMI20011744A1 (en) 2001-08-09 2001-08-09 DRUGS FOR VASCULOPATHIES
ITMI01A001744 2001-08-09

Publications (2)

Publication Number Publication Date
WO2003013499A2 true WO2003013499A2 (en) 2003-02-20
WO2003013499A3 WO2003013499A3 (en) 2003-12-31

Family

ID=11448261

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/008374 WO2003013499A2 (en) 2001-08-09 2002-07-26 Drugs for vasculopaties

Country Status (3)

Country Link
AU (1) AU2002333276A1 (en)
IT (1) ITMI20011744A1 (en)
WO (1) WO2003013499A2 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005011646A2 (en) * 2003-07-31 2005-02-10 Nicox S.A. Nitrooxy derivatives of losartan, valsatan, candesartan, telmisartan, eprosartan and olmesartan as angiotensin-ii receptor blockers for the treatment of cardiovascular diseases
EP1709155A2 (en) * 2003-12-31 2006-10-11 Khosrow Kashfi Compounds and compositions for treating dysproliferative diseases, and methods of use thereof
US7163958B2 (en) * 2002-07-03 2007-01-16 Nitromed Inc. Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
US7220749B2 (en) 2002-06-11 2007-05-22 Nitromed, Inc. Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
EP2075011A2 (en) 2004-08-26 2009-07-01 Piramal Life Sciences Limited Prodrugs Containing Bio-Cleavable Linkers
EP2266623A2 (en) 2004-08-26 2010-12-29 Piramal Life Sciences Limited Prodrugs containing novel bio-cleavable linkers
US8236820B2 (en) 2007-08-10 2012-08-07 Basil Rigas Anti-inflammatory compounds and uses thereof
RU2560144C2 (en) * 2006-02-03 2015-08-20 Никокс Сайенс Ирландия Nitrogen oxide-releasing compounds

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004484A1 (en) * 1992-08-20 1994-03-03 Corlay S.L. Nitric esters of derivatives of the 2-(2,6-di-halophenylamino)phenylacetic acid and process for their preparation
WO1995009831A1 (en) * 1993-10-06 1995-04-13 Nicox S.A. Nitric esters having anti-inflammatory and/or analgesic activity and process for their preparation
WO1996032946A1 (en) * 1995-04-19 1996-10-24 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
WO2000025776A1 (en) * 1998-10-30 2000-05-11 Nitromed, Inc. Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use
WO2000051988A1 (en) * 1999-03-02 2000-09-08 Nicox S.A. Nitroxyderivatives having antiinflammatory, analgesic and antithrombotic activity
WO2000061537A2 (en) * 1999-04-13 2000-10-19 Nicox S.A. Pharmaceutical compounds
WO2001012584A2 (en) * 1999-08-12 2001-02-22 Nicox S.A. Pharmaceutical compounds

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004484A1 (en) * 1992-08-20 1994-03-03 Corlay S.L. Nitric esters of derivatives of the 2-(2,6-di-halophenylamino)phenylacetic acid and process for their preparation
WO1995009831A1 (en) * 1993-10-06 1995-04-13 Nicox S.A. Nitric esters having anti-inflammatory and/or analgesic activity and process for their preparation
WO1996032946A1 (en) * 1995-04-19 1996-10-24 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
WO2000025776A1 (en) * 1998-10-30 2000-05-11 Nitromed, Inc. Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use
WO2000051988A1 (en) * 1999-03-02 2000-09-08 Nicox S.A. Nitroxyderivatives having antiinflammatory, analgesic and antithrombotic activity
WO2000061537A2 (en) * 1999-04-13 2000-10-19 Nicox S.A. Pharmaceutical compounds
WO2001012584A2 (en) * 1999-08-12 2001-02-22 Nicox S.A. Pharmaceutical compounds

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ADAMI A ET AL: "Vasodilating properties of a new non-steroidal anti-inflammatory drug, nitroflurbiprofen, on rat aortic rings." PHARMACOLOGICAL RESEARCH: THE OFFICIAL JOURNAL OF THE ITALIAN PHARMACOLOGICAL SOCIETY. ENGLAND 1996 APR-MAY, vol. 33, no. 4-5, April 1996 (1996-04), pages 239-244, XP001159734 ISSN: 1043-6618 *
FIORUCCI S ET AL: "Nitric oxide-releasing NSAIDs inhibit interleukin-1beta converting enzyme-like cysteine proteases and protect endothelial cells from apoptosis induced by TNFalpha." ALIMENTARY PHARMACOLOGY & THERAPEUTICS, vol. 13, no. 3, March 1999 (1999-03), pages 421-435, XP002933651 ISSN: 0269-2813 *
JANERO D R: "Nitric oxide (NO)-related pharmaceuticals: Contemporary approaches to therapeutic no modulation" FREE RADICAL BIOLOGY AND MEDICINE 15 MAY 2000 UNITED STATES, vol. 28, no. 10, 15 May 2000 (2000-05-15), pages 1495-1506, XP001159735 ISSN: 0891-5849 *
MAFFIA PASQUALE ET AL: "Beneficial effects of NO-releasing derivative of flurbiprofen (HCT-1026) in rat model of vascular injury and restenosis." ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, vol. 22, no. 2, February 2002 (2002-02), pages 263-267, XP001159163 February, 2002 ISSN: 1079-5642 *
MUSCARA MARCELO N ET AL: "Antihypertensive properties of a nitric oxide-releasing naproxen derivative in two-kidney, one-clip rats." AMERICAN JOURNAL OF PHYSIOLOGY, vol. 279, no. 2 Part 2, August 2000 (2000-08), pages H528-H535, XP008018686 ISSN: 0002-9513 *
NAPOLI CLAUDIO ET AL: "Effects of nitric oxide-releasing aspirin versus aspirin on restenosis in hypercholesterolemic mice." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 98, no. 5, 27 February 2001 (2001-02-27), pages 2860-2864, XP001159738 February 27, 2001 ISSN: 0027-8424 *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7220749B2 (en) 2002-06-11 2007-05-22 Nitromed, Inc. Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
US7589124B2 (en) 2002-06-11 2009-09-15 Nicox, S.A. Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
US8088762B2 (en) 2002-07-03 2012-01-03 Nicox S.A. Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
US7883714B2 (en) 2002-07-03 2011-02-08 Nicox S.A. Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
US7163958B2 (en) * 2002-07-03 2007-01-16 Nitromed Inc. Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
US8304409B2 (en) 2002-07-03 2012-11-06 Nicox S.A. Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
US8222277B2 (en) 2002-07-03 2012-07-17 Nicox S.A. Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
JP2007500684A (en) * 2003-07-31 2007-01-18 ニコックス エス エイ Nitrooxy derivatives of losartan, valsartan, candesartan, telmisartan, eprosartan and olmesartan as angiotensin-II receptor blockers for the treatment of cardiovascular disease
WO2005011646A3 (en) * 2003-07-31 2005-04-21 Nicox Sa Nitrooxy derivatives of losartan, valsatan, candesartan, telmisartan, eprosartan and olmesartan as angiotensin-ii receptor blockers for the treatment of cardiovascular diseases
WO2005011646A2 (en) * 2003-07-31 2005-02-10 Nicox S.A. Nitrooxy derivatives of losartan, valsatan, candesartan, telmisartan, eprosartan and olmesartan as angiotensin-ii receptor blockers for the treatment of cardiovascular diseases
EP1709155A2 (en) * 2003-12-31 2006-10-11 Khosrow Kashfi Compounds and compositions for treating dysproliferative diseases, and methods of use thereof
EP1709155A4 (en) * 2003-12-31 2007-10-31 Khosrow Kashfi Compounds and compositions for treating dysproliferative diseases, and methods of use thereof
US7585997B2 (en) 2003-12-31 2009-09-08 Chesterford Enterprises Limited Compounds and compositions for treating dysproliferative diseases, and methods of use thereof
EP2075011A2 (en) 2004-08-26 2009-07-01 Piramal Life Sciences Limited Prodrugs Containing Bio-Cleavable Linkers
EP2269657A2 (en) 2004-08-26 2011-01-05 Piramal Life Sciences Limited Prodrugs containing novel bio-cleavable linkers
EP2266625A2 (en) 2004-08-26 2010-12-29 Piramal Life Sciences Limited Prodrugs Containing Novel Bio-Cleavable Linkers
EP2266622A2 (en) 2004-08-26 2010-12-29 Piramal Life Sciences Limited Prodrugs containing novel bio-cleavable linkers
EP2266623A2 (en) 2004-08-26 2010-12-29 Piramal Life Sciences Limited Prodrugs containing novel bio-cleavable linkers
RU2560144C2 (en) * 2006-02-03 2015-08-20 Никокс Сайенс Ирландия Nitrogen oxide-releasing compounds
US8236820B2 (en) 2007-08-10 2012-08-07 Basil Rigas Anti-inflammatory compounds and uses thereof

Also Published As

Publication number Publication date
AU2002333276A1 (en) 2003-02-24
WO2003013499A3 (en) 2003-12-31
ITMI20011744A0 (en) 2001-08-09
ITMI20011744A1 (en) 2003-02-09

Similar Documents

Publication Publication Date Title
EP0637959B1 (en) Soluble analogs of probucol
US4260769A (en) 5,5-Diphenylhydantoins
JP2001527072A (en) Chelating agents releasing nitric oxide and their therapeutic use
US5480888A (en) Inhibitor for restenosis after percutaneous coronary arterioplasty
PT1642885E (en) Use of a pharmaceutical composition containing a para-aminophenyl acetic acid derivative for treating inflammatory conditions of the gastrointestinal tract
NZ257557A (en) Tromethamine salt of (+)-(s)-2-(3-benzoyl phenyl)propionic acid and pharmaceutical compositions, preparation and the use thereof as an analgesic agent
AU2018230805B2 (en) Antimicrobial compounds, compositions, and uses thereof
US20220249463A1 (en) Methods of altering cardiac remodeling using compounds that promote glucose oxidation
JP2002537258A5 (en)
US6683112B2 (en) Gabapentin prodrugs and formulations
WO2003013499A2 (en) Drugs for vasculopaties
WO2004066998A1 (en) Stable solid medicinal composition for oral administration
US20040171592A1 (en) Organic nitrate-based compounds for the treatment of vasculopathies
CN111635315B (en) Antipyretic analgesic medicine and preparation method and application thereof
CN102548988A (en) Azilsartan organic amine salts, preparation method and use thereof
US5506264A (en) Zinc tranexamate compounds
JP3208437B2 (en) Cancer metastasis inhibitor
US20160101112A1 (en) Pharmaceutical composition comprising n1-cyclic amine-n5-substituted biguanide derivatives as an ingredient for preventing or treating fibrosis
EP3928835B1 (en) Water-soluble polymeric derivative of venetoclax
JPH0529209B2 (en)
IE68060B1 (en) Nitratoalkanecarboxylic acid derivatives a process for their preparation use thereof and medicaments containing them
JPH11302254A (en) 3,3-dipyridylacrylic acid amide derivative or its pharmaceutically admissible salt
CH654011A5 (en) PHOSPHORAMIDES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
WO2005039556A1 (en) Medicine for preventing and/or treating restenosis or reocclusion after blood circulation restoration
US20210317072A1 (en) H2o crystal forms of a tca cycle intermediate conjugate

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AU BA BB BG BR BZ CA CO CR CU CZ DM DZ EC EE GD GE HU ID IL IN IS JP KP KR LC LK LR LT MA MG MK MN MX NO NZ OM PH PL SG SI SK TN TR TT UA US UZ VN YU

Kind code of ref document: A2

Designated state(s): AE AG AL AU BA BB BG BR BZ CA CN CO CR CU CZ DM DZ EC EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MA MG MK MN MX NO NZ OM PH PL RO SG SI SK TN TR TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP